EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T-cell therapies to treat cancers, today announced a poster presentation at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting, November 6-10, 2019, in National Harbor, Maryland. The presentation will highlight the company’s proprietary ARTEMIS™ antibody T-cell receptor (AbTCR) platform used to develop ET140202 for the treatment of hepatocellular carcinoma (HCC), the most predominant type of liver cancer. ET140202 features ARTEMIS™ T-cell receptors engineered with a TCR-mimic antibody to target the alpha-fetoprotein (AFP) peptide/ major histocompatibility complex (MHC) on HCC cancer cells.
SITC Poster Presentation Details:
Title: ET140202 T-cell Therapy for the Treatment of Liver Cancer is Built upon a Novel Antibody-T cell Receptor (AbTCR) ARTEMIS™ T-cell Platform |
Poster Presentation Date: Saturday, November 9, 2019 |
Poster Presentation Time: 12:35 – 2:05 pm EST and 7:00 – 8:30 pm EST |
Presenter: Jun Cui, Ph.D. |
Poster Number: P166 |
Abstract Category: Cellular Therapies |
Location: Poster Hall (Prince George AB) |
ABOUT EUREKA THERAPEUTICS, INC.
Eureka Therapeutics, Inc. is a privately held clinical stage biotechnology company focused on developing novel T-cell therapies to treat cancers. Its core technology centers around its proprietary ARTEMIS™ AbTCR T-cell receptor platform and E-ALPHA® antibody discovery platform for the discovery and development of potentially safer and more effective T-cell therapies for the treatment of multiple solid and hematologic tumors. The company has started a Phase I/II US multicenter clinical trial of its lead asset ET140202 in patients with advanced HCC.
Eureka Therapeutics, Inc. is headquartered in the San Francisco Bay Area. For more information on Eureka, please visit www.eurekatherapeutics.com.
